Pay in 4 interest-free payments of $45.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis
A significant increase of the animal lifespan in the test groups (from 4
PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%
is a potent and selective Rho kinase inhibitor
Roscovitine results in a dose-dependent reduction of CDK2 activity that at concentrations of 7
PHA-680632 182 ZK824190 is an orally availablePHA 680632 is a is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. PHA 680632 is also the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. PHA 680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well tolerated doses. Product
US$ 19.00
US$ 15.95
US$ 175.00
US$ 252.00
US$ 112727.50
US$ 249.50
US$ 114.50
US$ 149.50
US$ 144.00